After-hours trading on Friday, Evelo Biosciences, Inc. (Nasdaq: EVLO), the stock plunged -11/56% to $10.25. It’s not clear what happened that caused the share price to fall, and investors may want to take that as a warning sign.
A clinical-stage biotechnology company creating new oral medications with systemic effects prioritizes EDP1908 as its lead clinical candidate in oncology.
The Company said that it would cease patient recruitment for Phase 1/2 clinical trial of EDP1503 and finalize the study.
It revealed on additional interim clinical data from EDP1503, treated with pembrolizumab in TNBC patients with its Phase 1/2 open study, were presented in a poster session at the San Antonio Breast Cancer Symposium (SABCS) 2020 Virtual Meeting. In the 12 patients who received EDP1503 at a higher dose, as of a cutoff date of October 30, 2020, the response rate was 17 percent, with a disease control rate of 25%.
It suggests that the small intestinal axis, SINTAXTM, can be targeted using oral, gut-restricted medicines.